C12N 2796/00
Viruses not covered by groups c12n2710/00 - c12n2795/00
Official title: Viruses not covered by groups C12N2710/00 - C12N2795/00
C12N2796/00 (Viruses not covered by groups c12n2710/00 - c12n2795/00) appears on 14 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 24
- Assignees
- 24
- Inventors
- 48
- Latest grant
- 8 Mar 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 2 | 5 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 4 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 3 | 2 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids8 Mar 2022US 11,268,071 B2Merck Sharp & Dohme Corp.
- Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin24 Dec 2019US 10,512,684 B2Bavarian Nordic A/S
- Methods of producing viruses22 Oct 2019US 10,450,544 B2Benchmark Animal Health Limited
- Method of making a vaccine22 Jan 2019US 10,183,073 B1Hyper Light Technologies, LLC
- Truncated L1 protein of human papillomavirus type 629 Aug 2017US 9,745,351 B2Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- RNA Vectors with Hairpin-like Inserts4 Jan 2024US 2024/0002871 A1Silvec Biologics Inc.
- Inactivated virus vaccine microneedle product as well as preparation method and application thereof7 Sep 2023US 2023/0277826 A1Healthina Stem Cell Industry Platform (Tianjin) Limited
- Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids17 Dec 2020US 2020/0392468 A1Merck Sharp & Dohme Corp.
- Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids6 Feb 2020US 2020/0040310 A1Merck Sharp & Dohme Corp.
- Culture medium of viruses for human vaccines have to consist of human cells from placenta and/or from umbilical cord of a fetus of the blood type 0 Rh- and of the mother of the blood type 0 Rh- (both, fetus and mother, must be of the blood type 0 Rh-)18 Jul 2019US 2019/0218521 A1
Most cited
By later US patents
- Template reporter bacteriophage platform and multiple bacterial detection assays based thereon22US 7,244,612 B2University of Wyoming · 2007
- Preparation of vaccines using photosensitizer and light10US 8,759,092 B2Terumo BCT Biotechnologies, LLC · 2014
- Lipophilic quenching of viral inactivating agents9US 6,150,109 AV. I. Technologies, Inc. · 2000
- Preparation of vaccines using a photosensitizer and light3US 7,186,543 B1Gambro AB · 2007
- Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes3US 9,517,261 B2Deutsches Krebsforschungszentrum · 2016